Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the commercialization of its neuromodulation implant for rheumatoid art | Shortly ...